ZIVO Bioscience Achieves Promising Results in Coccidiosis Treatment for Broiler Chickens’
In an era where sustainable and responsible farming practices are paramount, ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech and agtech research and development company, has announced positive outcomes from its recently conducted 42-day confirmatory study on a novel coccidiosis treatment for broiler chickens. Coccidiosis, a significant parasitic disease affecting poultry, is known to cause substantial economic losses in the poultry industry by impacting the growth and overall health of birds. This study was conducted in collaboration with a major global animal health company and was designed to replicate real-world poultry production environments.
A Collaborative Endeavor in Animal Health
ZIVO, renowned for its commitment to developing therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, launched this study to validate the efficacy of its non-antibiotic, immune-modulating treatment for coccidiosis. The collaboration with a major global player in the animal health industry enhances the credibility of this research and underscores the growing interest in innovative, sustainable alternatives to traditional animal healthcare products.
Overview of the Study
The study was meticulously designed to assess the performance of ZIVO’s proprietary treatment over a 42-day period. Broiler chickens, which are raised specifically for meat production, were selected as the subject of the study due to their susceptibility to coccidiosis. The real-world conditions simulated in the trial were crucial in ensuring that the results would be applicable to commercial poultry farming practices.
ZIVO’s treatment stands out in that it is focused on immune modulation rather than the use of antibiotics, which is becoming increasingly important given growing concerns over antibiotic resistance and the push for more sustainable livestock production techniques. By leveraging the unique properties of algal cultures, ZIVO aims to provide poultry producers with an effective means of managing coccidiosis while adhering to modern farming principles.
Results and Implications
The results from the study were promising; specific details regarding the degree of effectiveness are yet to be disclosed. However, the favorable outcomes signal a potentially significant advancement in animal health solutions tailored to improve broiler chicken welfare and enhance production efficiency. If successful, ZIVO’s treatment could lead to better health management in poultry operations, reducing the need for conventional antibiotics and promoting a more ethical approach to livestock rearing.
The Company’s Vision
ZIVO’s commitment to agricultural biotechnology is rooted in the belief that innovative research can lead to more effective and environmentally sound agricultural practices. The company aims to revolutionize the animal health sector with its proprietary technologies, driving advances in livestock management that align with both economic viability and animal welfare.
As the agriculture industry faces increasing pressures to incorporate sustainable practices, ZIVO’s latest study could position them as a frontrunner in the development of non-antibiotic therapies within the poultry sector. The results of this study are set to be a game-changer, supporting the overarching goal of enhancing poultry health and productivity without relying on traditional antibiotic treatments.
Conclusion
As ZIVO Bioscience continues to push the boundaries of agricultural research and development, its recent success in the realm of coccidiosis treatment for broiler chickens highlights the potential of biotechnological advancements to reshape the future of animal health. The collaboration with a major global animal health company not only amplifies the impact of ZIVO’s findings but also sheds light on a larger trend within the industry a shift toward more sustainable, responsible practices in poultry farming.
Comments